NCT07674654招募中3 期
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 1,000
- 试验地点
- 339
- 主要终点
- Proportion of participants with at least one treatment-emergent adverse event (TEAE)
研究概览
简要总结
This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant completing an acute treatment trial of elismetrep (Study K-304 P003; attending the EoS Visit 3 within the allowed visit window of the acute treatment study), treated a qualifying migraine in that study, was at least 80% compliant with the daily e-Diary 'check-ins' in the base study and completed the 2-hour and 4-hour post-dose assessments in the eDiary.
- •Note: If a subject treats their qualifying migraine in the base study within 5 days of randomization (i.e. ≤ 4 daily check-ins should have been completed in the eDiary), they are eligible for this study if they missed 1 daily check-in, even though compliance was <80%;
- •Participant voluntarily agrees to participate in the study by giving written informed consent;
- •Participant is able to read, understand, and complete the study questionnaires and diary;
- •Participant is willing and able to comply with the study schedule of visits, all trial procedures and restrictions;
- •Participant is willing to use his/her own personal, qualified smartphone to download any specific eDiary applications for use for the entire duration of the study;
- •For females of reproductive potential (as determined in the base study), continues to agree to remain abstinent from heterosexual activity or a. Agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the EoS visit.
- •Acceptable methods of birth control are:
- •i. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal. ii. Progestogen-only hormonal contraception associated with inhibition of ovulation: oral; injectable; implantable; intrauterine device; intrauterine hormone-releasing system; bilateral tubal occlusion; vasectomized partner; sexual abstinence*; progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action; male or female condom with or without spermicide; cap, diaphragm or sponge with spermicide; a combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods).
- •Abstinence can be used as the sole method of contraception if it is in line with the participant's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.
排除标准
- •Is a female who is pregnant, breast-feeding, or intends to become pregnant during the planned course of the study. Note: Participants must have a negative urine pregnancy result at the base study EoS/Visit 3 (i.e., pre-randomization for this study);
- •Has, at the time of the base study EoS/Visit 3, had any change in medical history or a laboratory finding since screening in the acute treatment study that in the opinion of the investigator renders the participant unsuitable for this study (e.g., development of a finding that would have precluded participation in the base acute treatment study);
- •Participant is at imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicidality Severity Rating Scale (C-SSRS) taken during the base study E0S/Visit 3, or of harm to others in the opinion of the investigator. Participants must be excluded if they report suicidal ideation with intent, with or without a plan (i.e., Type 4 or 5 on the C-SSRS) in 'since last version' version of the C-SSRS;
- •Participant is currently in violation of study requirements for prohibited and permissible concomitant medications or treatments (not already specified in other criteria) or is anticipated to violate these requirements during trial participation) as assessed for the base study E0S/Visit 3;
- •Has any major surgery scheduled for the duration of the trial;
- •Has any other unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with the interpretation of efficacy and/or safety results;
- •At Visit 1, has an open/ongoing adverse event from the base study EoS visit;
- •Experienced a serious adverse event in the base study;
- •Has previous participation in this trial. Participation is defined as signed informed consent following completion of the base study EoS/Visit 3 procedures.
研究组 & 干预措施
Elismetrep 20 mg
Experimental
干预措施: Elismetrep (Drug)
Elismetrep 10 mg
Experimental
干预措施: Placebo (Drug)
Elismetrep 10 mg
Experimental
干预措施: Elismetrep (Drug)
结局指标
主要结局
Proportion of participants with at least one treatment-emergent adverse event (TEAE)
时间窗: Through study completion, an average of 1 year
Proportion of participants with at least one treatment-emergent serious adverse event (SAE)
时间窗: Through study completion, an average of 1 year
Proportion of participants with TEAEs leading to study drug discontinuation
时间窗: Through study completion, an average of 1 year
Proportion of participants with TEAEs that occur in at least 5% of treated participants in either treatment arm
时间窗: Through study completion, an average of 1 year
次要结局
未报告次要终点
研究者
研究点 (339)
Loading locations...
相似试验
Enrolling By Invitation
不适用
"Real-world Assessment of BP Control in Patients With Hypertension by the Netrod RDN System" - REACH-RDNHypertensionNCT07273877Shanghai Golden Leaf MedTec Co. Ltd1,000
招募中
3 期
Long Term Study of Ecopipam Tablets in Children, Adolescents and Adults with Tourette’s Disorder2023-503545-67-00Emalex Biosciences Inc.38
招募中
3 期
ELEVATE UC OLE: An Open-Label Extension Study for Treatment of Moderately to Severely Active Ulcerative ColitisUlcerative Colitis2024-515156-21-00Arena Pharmaceuticals Inc.298
招募中
2 期
An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants with Rheumatoid Arthritismoderate to severe rheumatoid arthritis (RA)2025-523579-47-00F. Hoffmann-La Roche AG46
招募中
2 期
A Study to Assess the Long-Term Efficacy and Safety of Afimkibart (RO7790121) in Patients with Atopic Dermatitis who participated in previous Afimkibart Clinical TrialsAtopic Dermatitis2025-520771-59-00F. Hoffmann-La Roche AG49